ReviewFrontiers in aging neuroscience2026
Mitochondrial transplantation for delirium superimposed on dementia: from pathogenic mechanisms to clinical translation challenges.
Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delirium Superimposed on Dementia (DSD) is a common neuropsychiatric disorder in hospitalized elderly populations with poor prognosis, which can accelerate cognitive decline and increase mortality. Despite its clinical significance, there is a lack of effective therapeutic methods in clinical practice. Mitochondrial dysfunction, characterized by impaired energy metabolism, excessive reactive oxygen species (ROS) production and neuroinflammation activation, has been suggested as a potentially critical pathogenic link in DSD. As an emerging organelle-based therapy, mitochondrial transplantation (MTT) restores cellular energy homeostasis and mitigates oxidative stress by delivering functional mitochondria into damaged cells, thus holding promising potential as a future strategy for DSD treatment. This review systematically summarizes the hypothesized pathological role of mitochondrial dysfunction in DSD and the technical system of MTT, including mitochondrial isolation, purification, preservation and delivery strategies. We further elaborate on the plausible neuroprotective mechanisms of MTT and its preclinical evidence in neurodegenerative disease models relevant to, but distinct from, DSD. Additionally, we comprehensively analyze the technical, immunological and clinical challenges of MTT in DSD treatment, and propose targeted solutions and future research directions. This review constructs a theoretical framework for the hypothetical translation of MTT from basic research to clinical application in DSD, and provides novel insights for the development of future etiological therapies for this devastating disorder.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.